scholarly journals Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials

2018 ◽  
Vol 24 (8) ◽  
pp. S58-S59
Author(s):  
Ayman Samman Tahhan ◽  
Muthiah Vaduganathan ◽  
Stephen Greene ◽  
Gregg Fonarow ◽  
Mona Fiuzat ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
Ethnic Minorities ◽  
Older Patients ◽  
Racial And Ethnic Minorities

Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials

2018 ◽  
Vol 3 (10) ◽  
pp. 1011 ◽  
Author(s):  
Ayman Samman Tahhan ◽  
Muthiah Vaduganathan ◽  
Stephen J. Greene ◽  
Gregg C. Fonarow ◽  
Mona Fiuzat ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
Ethnic Minorities ◽  
Older Patients ◽  
Racial And Ethnic Minorities

Pharmacotherapy of Chronic Heart Failure in the Elderly: A Review of the Evidence

2010 ◽  
Vol 2 ◽  
pp. CMT.S2794
Author(s):  
Toni L. Ripley ◽  
Thomas A. Hennebry
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
Older Patients ◽  
The Elderly ◽  
The United States ◽  
Response To Therapy ◽  
Clinical Endpoints ◽  
Age Related ◽  
Prevalent Disease ◽  
To Receive

Heart failure (HF) is a very prevalent disease in the United States and in Europe, with the highest prevalence among older patients. Population estimates suggest substantial growth among the elderly over the next four decades. However, older patients are underrepresented in clinical trials evaluating HF therapies and are less likely to receive the medications shown in these trials to reduce the morbidity and mortality associated with HF. Age-related differences exist in cardiovascular function that may affect disease progression, clinical presentation, and/or response to therapy. Further, medication use in older patients is complicated by physiologic changes in pharmacokinetics and the presence of multiple co-morbidities, which leads to polypharmacy and the related complications. We reviewed the pharmacotherapy clinical trials in HF to review the results specifically in older patients. Trials were included in this review if clinical endpoints were evaluated, if data regarding the participants’ age was reported, and if the intervention studied was in a medication class that is generally recommended for patients with HF by published guidelines. Although some non-randomized data shows benefits of standard therapies may be maintained among patients with HF ≥ 60 years old, the randomized controlled trials that have been published to date showed no benefit and no harm in this group. Cautious HF management among older patients is critical as additional evidence is pursued.

scholarly journals Recruitment of racial and ethnic minorities to clinical trials conducted within specialty clinics: an intervention mapping approach

Trials ◽  
2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Rossybelle P. Amorrortu ◽  
Mariana Arevalo ◽  
Sally W. Vernon ◽  
Arch G. Mainous ◽  
Vanessa Diaz ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Ethnic Minorities ◽  
Intervention Mapping ◽  
Racial And Ethnic Minorities ◽  
Mapping Approach

scholarly journals The Persistent Exclusion of Older Patients From Ongoing Clinical Trials Regarding Heart Failure

2011 ◽  
Vol 171 (6) ◽  
Author(s):  
Antonio Cherubini ◽  
Joaquim Oristrell ◽  
Xavier Pla ◽  
Carmelinda Ruggiero ◽  
Roberta Ferretti ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
Older Patients

Abstract LB-012: US cancer centers of excellence coordination of operational strategies contribute to enhanced accrual of racial and ethnic minorities in clinical trials

2019 ◽  
Author(s):  
Jeanne M. Regnante ◽  
Nicole A. Richie ◽  
Lola Fashoyin-Aje ◽  
Laura Lee Hall ◽  
Quita Highsmith ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Ethnic Minorities ◽  
Centers Of Excellence ◽  
Operational Strategies ◽  
Cancer Centers ◽  
Racial And Ethnic Minorities

scholarly journals Exploring the Engagement of Racial and Ethnic Minorities in HIV Treatment and Vaccine Clinical Trials: A Scoping Review of Literature and Implications for Future Research

2020 ◽  
Vol 34 (9) ◽  
pp. 399-416
Author(s):  
Sarah Bauerle Bass ◽  
Paul D'Avanzo ◽  
Mohammed Alhajji ◽  
Nicole Ventriglia ◽  
Aurora Trainor ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Ethnic Minorities ◽  
Scoping Review ◽  
Hiv Treatment ◽  
Future Research ◽  
Review Of Literature ◽  
Racial And Ethnic Minorities

scholarly journals Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction

2019 ◽  
Vol 5 (2) ◽  
pp. 70-73 ◽  
Author(s):  
Davide Stolfo ◽  
Gianluigi Savarese
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
Ejection Fraction ◽  
Older Patients ◽  
Randomised Clinical Trials ◽  
World Population ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin ◽  
Reduced Ejection Fraction ◽  
Raas Inhibitors

Patients enrolled in randomised clinical trials may not be representative of the real-world population of people with heart failure (HF). Older patients are frequently excluded and this limits the strength of evidence which supports the use of specific HF treatments in this patient group. Lack of evidence together with fear of adverse effects, drug interactions and lower tolerance may lead to the undertreatment of older patients and a less favourable outcome. Renin–angiotensin–aldosterone system (RAAS) inhibitors are the cornerstone of treatment for patients with HF with reduced ejection fraction (HFrEF), but despite the class I recommendation for all patients regardless of age in the guidelines, there are signs that RAAS inhibitors are underused among older patients. Large registry- based studies suggest that RAAS inhibitors may be at least as effective in older patients as younger ones, but these findings need to be confirmed by randomised clinical trials.

Abstract LB-012: US cancer centers of excellence coordination of operational strategies contribute to enhanced accrual of racial and ethnic minorities in clinical trials

2019 ◽  
Author(s):  
Jeanne M. Regnante ◽  
Nicole A. Richie ◽  
Lola Fashoyin-Aje ◽  
Laura Lee Hall ◽  
Quita Highsmith ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Ethnic Minorities ◽  
Centers Of Excellence ◽  
Operational Strategies ◽  
Cancer Centers ◽  
Racial And Ethnic Minorities
Sign in / Sign up

Export Citation Format

Share Document